HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.08.13.248872: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication Contamination: All cell lines were previously tested for mycoplasma contamination and incubated in Dulbecco’s modified Eagle’s medium at 37 °C under a humidified atmosphere with 5% CO2. Table 2: Resources
Antibodies Sentences Resources Reagents and antibodies: His-tagged SARS-2-S (S1+S2 ECD; YP_009724390.1;Val16-Pro1213; 40589-V08B1), SARS-2-S1 (YP_009724390.1;Val16-Arg685; 40591-V08H), and SARS-2-S2 (ECD; YP_009724390.1; Ser686-Pro1213; 40591-V08B) proteins were from Sino Biological. S1+S2suggested: NoneECDsuggested: …SciScore for 10.1101/2020.08.13.248872: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication Contamination: All cell lines were previously tested for mycoplasma contamination and incubated in Dulbecco’s modified Eagle’s medium at 37 °C under a humidified atmosphere with 5% CO2. Table 2: Resources
Antibodies Sentences Resources Reagents and antibodies: His-tagged SARS-2-S (S1+S2 ECD; YP_009724390.1;Val16-Pro1213; 40589-V08B1), SARS-2-S1 (YP_009724390.1;Val16-Arg685; 40591-V08H), and SARS-2-S2 (ECD; YP_009724390.1; Ser686-Pro1213; 40591-V08B) proteins were from Sino Biological. S1+S2suggested: NoneECDsuggested: NoneYP_009724390.1;Val16-Pro1213suggested: None40589-V08B1suggested: NoneSARS-2-S1suggested: NoneYP_009724390.1;Val16-Arg685suggested: None40591-V08Hsuggested: NoneSARS-2-S2suggested: NoneAn antibody against ACE2 for FACS (21115-1-AP; 1:100 dilution) was from Proteintech. 21115-1-APsuggested: (Proteintech Cat# 21115-1-AP, RRID:AB_10732845)A PE anti-His antibody (362603, clone J095G46; 1;100 dilution) and an antibody against SR-B1 for FACS (363208, clone m1B9; dilution 1:100) were from Biolegend. anti-Hissuggested: (BioLegend Cat# 362603, RRID:AB_2563634)SR-B1 for FACS ( 363208suggested: NoneThe SARS-CoV-2 S1 antibody (40150-R007) for confocal microscopy was from Sino Biological. S1suggested: NoneThen, anti-rabbit or anti-mouse HRP-conjugated antibodies were applied after 3 washes and the antigen-antibody complexes were visualized using chemilumines cence. anti-rabbitsuggested: Noneanti-mouse HRP-conjugatedsuggested: NoneFlow cytometry for surface SR-B1 or ACE2 expression analysis: Cells were washed with PBS 2 times and incubated with APC-conjugated (APC anti-SR-B1) antibody (1:100) or anti-ACE2 antibody (1:100) followed by a secondary incubation with donkey-anti-rabbit antibody (1:200) conjugated to Alexa Flour 488. antibodysuggested: NoneAfter incubating at RT for 30 min, the cells were washed two times with PBS containing 2% FBS and then incubated for 30 min at RT with a PE-conjugated antibody (PE anti-His tag). anti-His tag) .suggested: NoneAfter blocking in 1% normal goat serum, the sections were incubated with ACE2 or SR-B1 monoclonal antibodies at 4□°C overnight in a humidified chamber, which was followed by an incubation with HRP-labeled goat anti-mouse IgG secondary antibody (Beijing ZSGB Biotechnology, ZDR-5307). ACE2suggested: NoneSR-B1suggested: Noneanti-mouse IgGsuggested: NoneSubsequently, the sections were incubated with a goat anti-rabbit IgG secondary antibody (HRP) (Beijing ZSGB Biotechnology, PV9001) for 60 min and then visualized with 3,30-diaminobenzidine tetrahydrochloride (DAB). anti-rabbit IgGsuggested: (ZSGB-Bio Cat# PV-9001, RRID:AB_2868452)Experimental Models: Cell Lines Sentences Resources , Vero E6 (CRL-1568), MDCK (CCL-34) and Hepa 1-6 (CRL-1830 Vero E6suggested: NoneMDCKsuggested: NonePseudovirus production: All pseudoparticles were generated in 293T cells transfected with the HIV backbone vector pNL4-3. 293Tsuggested: NoneFor chemicals and antibodies, Vero E6 or Huh-7 cells (1.6 ×105 cells/mL) were cultured in a 96-well plate at 37 °C overnight. Huh-7suggested: NoneFor SR-B1 expression, Vero cells (1.6 ×105 cells/mL) were transfected with a plasmid encoding SR-B1, while Huh-7 cells (1.6 ×105 cells/mL) were transfected with siRNA oligos for SR-B1. Verosuggested: NoneSoftware and Algorithms Sentences Resources Data were fitted to saturation binding equations using GraphPad Prism 6. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Acoustic Focusing cytometer using Flowjo V10.0.7. Flowjosuggested: (FlowJo, RRID:SCR_008520)Statistical methods: In the present study, GraphPad Prism 8.0 was used for statistical calculations and data plotting. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-